Evaluation of Vitamin D-levels and Bone Mineral Density in Lymphoma and Solid Tumors of Childhood after Treatment

Authors

  • Ozge Artan Department of Pediatrics, Health Science University, Ankara City Hospital, Ankara, Turkey. http://orcid.org/0000-0002-9773-5497
  • Suna Emir

DOI:

https://doi.org/10.31964/mltj.v7i2.403

Keywords:

25 hydroxy vitamin D, bone mineral density, lymphoma, solid tumor

Abstract

As the survival rate of childhood cancers increases, late effects of the treatment are becoming significantly more critical. The aim of this study is to evaluate serum 25 Hydroxy Vitamin D levels and bone mineral density (BMD) of patients with lymphoma and solid tumors. In this study, we included patients diagnosed with cancer in our pediatric oncology department between 2004 and 2013. These patients were all in remission and completed their treatment. Patient data were collected from corresponding medical files. Vitamin D levels, BMD measurements and other laboratory tests were performed prospectively. The study group consisted of 105 patients who completed treatment at least one year ago. Overall, 59.6 % of the subjects were found to have vitamin D levels less than 20 ng/mL. When the factors affecting vitamin D deficiency were evaluated, there were not any factor related to vitamin D deficiency. However, a positive correlation was observed in the blood sampling time, namely test results taken in summer months (April-September) were higher. In our study, bone mineralization disorder (low BMD) was found in 44.4% of the patients. In addition, we observed that bone health was significantly affected in children who recovered from cancer. 59.6 % of the vitamin D deficiency rate was found to be higher than the similar age group in our country. To our knowledge, this is also the lowest vitamin D levels in children with cancer compared to previously published studies. The rate of low BMD was determined as 44.4%, similar to earlier studies.

References

Bhatia, J., Blatt J., Meadows A. (2006). Late effects of childhood cancer and its treatment. In: Pizzo PA, Poplack DG (eds). Principles and practice of pediatric oncology. 5th edition. Philadelphia: Lippincott Williams and Wilkins,1490-1514.

Cohen, L. E. (2003). Endocrine late effects of cancer treatment. Curr Opin Pediatr., 15:3-9.

Bircan, İ. (2003). Malign hastalıkların endokrin etkileri. Günöz H, Öcal G, Yordam N, Kurtoğlu S (editörler). Pediatrik endokrinoloji. 1. edition. Ankara: Pediatrik Endokrinoloji ve Oksoloji Derneği Yayınları, 623-38.

Nandagopal, R., Laverdière, C., Mulrooney, D., Hudson, MM., Meacham, L.(2008). Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res, 69:65-74.

Andıran, N., Çelik N., Akça H., Doğan G. (2012).Vitamin D deficiency in children and adolescents. J. Clin Pediatr Endocrinol; 4(1):25-29.

Choudhary, A., Chou, J., Heller, G., Sklar, C. (2013). Prevalence of vitamin D insufficiency in survivors of childhood cancer. Pediatr Blood Cancer, 60:1237-1239.

Sinha, A., Avery P., Turner S., Bailey S., Cheetham T. (2011). Vitamin D status in paediatric patients with cancer. Pediatr Blood Cancer, vol. 4:594-8.

Simmons, J.H., Chow E.J., Koehler E., Smith L.A. (2011).Significant 25-hydroxyvitamin D deficiency in childhood and adolescent survivors of acute lymphoblastic leukemia: treatment with hemotherapy compared with allogenic stem cell transplant. Pediatr Blood Cancer, 56(3);372-8.

Rossen, G.P., Beebe K.L., Sheibi G.Q. (2013). Vitamin D levels differ by cancer diagnosis and decline over time in survivors of childhood cancer. Pediatr Blood Cancer, 60(6);949-52.

Kaste, S.C., Ahn H., Liu T., et al. (2008). Bone mineral density deficits in pediatric patients treated for sarcoma. Pediatr Blood Cancer, 50:1032-8.

Othman, F., Guo C.Y., Webber C., Atkinson S.A., Barr R.D. (2002). Osteopenia in survivors of Wilms tumor. Int J Oncol, 20:827-33.

Sala, A., Talsma D., Webber C., et al. (2007). Bone mineral status after treatment of malignant lymphoma in childhood and adolescence. Eur. J. Cancer Care, 16:373-9.

Odame, I., Duckworth J., Talsma D., et al. (2006). Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood. Pediatr Blood Cancer, 46:357-62.

Maniadaki, I., Stiakaki E., Germanakis I., Kalmanti M. (2006). Evaluation of bone mineral density at different phases of therapy of childhood ALL. Pediatr Hematol Oncol, 23:11-8.

Kaste, S.C., Jones-Wallace D., Rose S.R., et al. (2001). Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia, 15:728-34.

Bechard, L.J., Gordon C., Feldman H.A., Venick R., Gura K., Guinan E.C., Duggan C.,(2015) Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation. Pediatr Blood Cancer, 62; 687-692.

Downloads

Additional Files

Published

2021-12-31

How to Cite

Artan, O., & Emir, S. (2021). Evaluation of Vitamin D-levels and Bone Mineral Density in Lymphoma and Solid Tumors of Childhood after Treatment. Medical Laboratory Technology Journal, 7(2), 174–181. https://doi.org/10.31964/mltj.v7i2.403

Issue

Vol. 7 No. 2 (2021): December

Section

Articles

License

Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:


BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.